Roche Diagnostics entered into acquisition agreement to acquire BioVeris, thus strengthening its product portfolio in the areas of life sciences research and development, patient self-testing, veterinary testing, drug discovery, drug development and clinical trials. The acquisition deal could worth up to US$600 M to BioVeris.